Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma.

导出 LinkOut

翻译打印收藏纠错

作者： Weihao,Chen ^[1] ; Jimin,Shi ^[1] ; Yi,Luo ^[2] ; Jian,Yu ^[3] ; Xiaoyu,Lai ^[4] ; Lizhen,Liu ^[1] ; Huarui,Fu ^[2] ; He,Huang ^[3] ; Yanmin,Zhao ^[4]

作者单位： Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. ^[1] Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, 311121, China. ^[2] Institute of Hematology, Zhejiang University, Hangzhou, China. ^[3] Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China. ^[4] Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. huanghe@zju.edu.cn. ^[5] Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, 311121, China. huanghe@zju.edu.cn. ^[6] Institute of Hematology, Zhejiang University, Hangzhou, China. huanghe@zju.edu.cn. ^[7] Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China. huanghe@zju.edu.cn. ^[8] Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. zjzhaoyanmin@163.com. ^[9] Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, 311121, China. zjzhaoyanmin@163.com. ^[10] Institute of Hematology, Zhejiang University, Hangzhou, China. zjzhaoyanmin@163.com. ^[11] Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China. zjzhaoyanmin@163.com. ^[12]